IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
5.96
-1.06 (-15.10%)
At close: Jun 26, 2026, 4:00 PM EDT
5.83
-0.13 (-2.18%)
After-hours: Jun 26, 2026, 7:59 PM EDT

Company Description

IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally.

The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.

It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors.

The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics.

IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.

IceCure Medical Ltd
IceCure Medical logo
Country Israel
Founded 2006
Industry Medical Devices
Sector Healthcare
Employees 69
CEO Eyal Shamir

Contact Details

Address:
7 Ha’Eshel St., PO Box 3163
Caesarea, 3079504
Israel
Phone 972 4 623 0333
Website icecure-medical.com

Stock Details

Ticker Symbol ICCM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $0.00
CIK Code 0001584371
CUSIP Number M53071136
ISIN Number IL0011224156
SIC Code 3841

Key Executives

Name Position
Eyal Shamir Chief Executive Officer and Director
Shay Levav Chief Operating Officer
Tlalit Bussi Tel-Tzure Vice President of Business Development and Global Marketing
Shad Good Vice President of Sales for North America
Meir Peleg Chief Financial Officer
Merav Nir Dotan Vice President of Human Resources
Galit Malik Vice President of Operations and Service

Latest SEC Filings

Date Type Title
Jun 26, 2026 6-K Report of foreign issuer
Jun 25, 2026 F-3 Filing
Jun 25, 2026 D Notice of Exempt Offering of Securities
Jun 25, 2026 6-K Report of foreign issuer
Jun 18, 2026 6-K Report of foreign issuer
Jun 2, 2026 6-K Report of foreign issuer
May 19, 2026 6-K Report of foreign issuer
May 13, 2026 6-K Report of foreign issuer
May 12, 2026 424B5 Filing
May 12, 2026 6-K Report of foreign issuer